Todd S. Wills, MD
Program Director, Infectious Disease Fellowship Program
Biographical Sketch | Areas of Expertise | Current Research | Publications
MD, University of South Florida College of Medicine, Tampa, Florida
Residency, Internal Medicine, University of North Carolina Hospitals, Chapel Hill, NC
Fellowship, Infectious Diseases, University of South Florida College of Medicine, Tampa, Florida
Phone: (813) 844-4187
FAX: (813) 844-7605
Areas of Expertise
Hillsborough County Health Department – Clinical Research Unit: 2001 – 2012
Ongoing Protocols (Principal Investigator):
A Multicenter, Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety of Maraviroc in Combination with Other Antriretroviral Agents in HIV-1-infected Subjects Co-infected with Hepatitis C and/or Hepatitis B Virus.
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of CS-9350-Boosted Atazanavir versus Ritonavir-boosted Atazanavir each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Ritonavir-boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antriretroviral Treatment-Naïve Adults.
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.
A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS 9137 (GS 9137/r) Administered in Combination with Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subjects.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857 in Combination with Optimized Background Therapy versus Optimized Background Therapy along with the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects. [Pfizer A4001027]
Ongoing Protocols (Co-Investigator)
A randomized, controlled, partially blinded Phase IIb dose-finding trial of TMC125, in HIV-1 infected subjects with documented genotypic evidence of resistance to currently available NNRTIs and with at least three primary PI mutations [ TMC125-C223]
A Phase II, Randomized, Blinded, 12-Week Comparison of Elvucitabine in Combination with Efavirenz and Tenofovir versus Lamivudine in Combination with Efavirenz and Tenofovir in HIV-1 Infected, Treatment-Naïve Subjects, with a 12-Week Extension Treatment Period [ACH443-015]
A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy. [SMART CPCRA 065]
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. This trial will be referred to as ARTEMIS. [TMC114-211]
A Phase IIb, Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral Naïve HIV-1 Infected Subjects [TMC278-204]
An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and were Treated for at least 48 Weeks [TMC125-C229]
A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of Epzicom versus Truvada Administered in Combination with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects” [EPZ104057] –HEAT
A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908/Ritonavir Given with Abacavir/Lamivudine Fixed Dose Combination. [COL100758]
A Probe Study to Evaluate the Safety, Tolerability, and Immunogenicity of the MRK Adenovirus Serotype 5 Vector (MRKAd5) Human Immunodeficiency Virus Type I (HIV-1) gag Vaccine in HIV-1 Infected Individuals. [Merck V520 – 014]
Wills TS, Vega V. Elvitegravir: A Once-daily inhibitor of HIV-1 Integrase. Expert Opin Invest Drugs 2012;21(3):395-401
Wills TS, Sinnott JT, Alrabaa S. "Viral Hemmorhagic Fevers" APIC Text of Infection Control and Epidemiology. Association for Professionals in Infection Control and Epidemiology. Philadelphia. 2009. 88-1 - 88-10
Wills TS, Lopez J, Billington A. Empyema Caused by Ralstonia Picketii in a Hemodialysis Patient. Clin Micro Newsletter 2007; 27(7):55-56
Irvine L, Wills TS. Streptobacillus moniliformis: A Mouse Trying to Become a Rat. Clin Micro Newsletter 2006; 28(15):118-20
Wills TS, Symes S. Chapter 18 "Cytomegalovirus Infections" HIV/AIDS Primary Care Guide ed. Beal J, Orick JJ, Norwalk CT: Crown House. 2006
Wills T, Goodrich JM. Cytomegalovirus. EMedicine.com. Available online. Updated May 11, 2009
Wills T. Don't Kiss and Swell: Managing Mono. ABC News. Available online. Updated August 8, 2007
Wills T, Jaworki MA. Norwalk Virus. eMedicine.com. Available online. Updated June 30, 2006.
D’Souza KR, Menezes L, Wills TS, D’Souza KM. Women infected with HIV and Human Papillomavirus (HPV): an emerging health problem in resource-constrained settings. American Public Health Association (APHA) 134th Annual Meeting and Exposition, Boston, MA, November 2006.
Tash K, Wills T, Sinnott J. Rahnella aquatis: A new niche? International Conference of Infectious Diseases. Lisbon, Portugal June 2006.
Pujari S, Wills T, Naik E, Menezes L, et al. Correlates of Anemia for HIV patients in the HAART era: a single center ambulatory clinical cohort in Pune, India. XVI International AIDS Conference – Abstract CD-ROM. Toronto August 2006.
Naik E, D’ Souza BS, Menezes L, Wills T, et. al. A collaboratively designed HIV mini-residency by US and Indian faculty. Association for Medical Education in Europe Conference, Genoa, Italy September 2006.
Menezes L, D’Souza K, Wills T, et al. Capacity-building: Indian physicians benefit from blended curriculum. Association for Medical Education in Europe Conference, Genoa, Italy, September 2006.
Nadler JP, Wills TS, Somboonwit C, et. al. Anemia prevalence among HIV patients: Anti-retroviral therapy and other risk factors. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment and the 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, France 2003.
Search Google Scholar for Publications by Dr. Wills